MARIETTA, Ga., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the following investor conferences:
H.C. Wainwright 25th Annual Global Investment Conference
Presentation: Tuesday, September 12, 2023 at 12:30 PM ET
Webcast: Click here to access
Northland Capital Markets Institutional Investor Conference (Virtual)
Participation: Tuesday, September 19, 2023
Cantor Fitzgerald Global Healthcare Conference 2023
Presentation: Wednesday, September 27, 2023 at 10:55 AM ET
Webcast: Click here to access
Institutional investors interested in meeting with senior management may contact their respective H.C. Wainwright, Northland Capital, or Cantor Fitzgerald representative.
A live webcast of each presentation will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the links above. A replay will be available on the Company’s website following the event.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.14 |
Daily Change: | 0.04 0.56 |
Daily Volume: | 353,119 |
Market Cap: | US$1.060B |
July 30, 2025 May 05, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load